We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50-day moving average price of $43.76 and a 200 day moving average price of $47.16.

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day. We recently compiled a list of the Top 11 CRISPR ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical... ByInvesting.com ...

Crispr Therapeutics (NASDAQ:CRSP) is involved in the kind of technology that promises to enable genetic programming. Horrible as this prospect is, I was more intrigued by the ...